Blue Owl Capital Holdings LP Sells 235,000 Shares of Mineralys Therapeutics, Inc. $MLYS

Blue Owl Capital Holdings LP lessened its position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 70.0% during the third quarter, Holdings Channel reports. The institutional investor owned 100,944 shares of the company’s stock after selling 235,000 shares during the quarter. Mineralys Therapeutics comprises approximately 1.2% of Blue Owl Capital Holdings LP’s portfolio, making the stock its 26th largest holding. Blue Owl Capital Holdings LP’s holdings in Mineralys Therapeutics were worth $3,828,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Smartleaf Asset Management LLC boosted its position in Mineralys Therapeutics by 198.2% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,017 shares of the company’s stock worth $40,000 after acquiring an additional 676 shares during the last quarter. Ameritas Investment Partners Inc. grew its stake in shares of Mineralys Therapeutics by 42.8% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,995 shares of the company’s stock worth $54,000 after acquiring an additional 1,197 shares in the last quarter. Police & Firemen s Retirement System of New Jersey raised its holdings in shares of Mineralys Therapeutics by 29.4% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 9,234 shares of the company’s stock valued at $125,000 after purchasing an additional 2,098 shares during the last quarter. ProShare Advisors LLC acquired a new stake in shares of Mineralys Therapeutics in the second quarter valued at approximately $141,000. Finally, Profund Advisors LLC bought a new stake in shares of Mineralys Therapeutics in the second quarter worth $164,000. Institutional investors own 84.46% of the company’s stock.

Insider Buying and Selling at Mineralys Therapeutics

In other news, CEO Jon Congleton sold 16,236 shares of the business’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $32.62, for a total transaction of $529,618.32. Following the transaction, the chief executive officer directly owned 639,151 shares in the company, valued at $20,849,105.62. The trade was a 2.48% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Adam Scott Levy sold 10,758 shares of the company’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $32.14, for a total transaction of $345,762.12. Following the completion of the sale, the chief financial officer directly owned 8,638 shares in the company, valued at approximately $277,625.32. The trade was a 55.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 340,748 shares of company stock worth $11,697,169 over the last quarter. 25.56% of the stock is currently owned by insiders.

Mineralys Therapeutics Trading Down 0.5%

NASDAQ MLYS opened at $26.59 on Friday. Mineralys Therapeutics, Inc. has a 12 month low of $10.19 and a 12 month high of $47.65. The stock has a 50 day moving average of $31.33 and a 200-day moving average of $34.93. The company has a market cap of $2.10 billion, a PE ratio of -9.01 and a beta of 0.57.

Analysts Set New Price Targets

Several research analysts recently commented on MLYS shares. Weiss Ratings restated a “sell (d-)” rating on shares of Mineralys Therapeutics in a report on Thursday, January 22nd. Stifel Nicolaus boosted their price target on shares of Mineralys Therapeutics from $45.00 to $52.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. Wells Fargo & Company increased their price objective on shares of Mineralys Therapeutics from $50.00 to $55.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 11th. Wall Street Zen cut Mineralys Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Finally, HC Wainwright lifted their target price on Mineralys Therapeutics from $52.00 to $56.00 and gave the company a “buy” rating in a research report on Wednesday, November 12th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $47.43.

Mineralys Therapeutics Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.